Venetoclax Reverses Negative Prognostic Impact of Splicing Factor Mutations for Patients with Acute Myeloid Leukemia
Mutations in splicing factor (SF) genes are classified as adverse risk in patients with acute myeloid leukemia (AML) within the European LeukemiaNet 2022 risk stratification tool. Now, an analysis of 994 patients ...
Non-Chemo Sequential Therapy Achieves High Remission in Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
Induction therapy with inotuzumab ozogamicin followed by consolidation with blinatumomab was highly effective and safe in older patients with newly diagnosed ...
Menin Inhibitor Revumenib Produces Strong Responses in R/R KMT2A-Rearranged Leukemia
The menin inhibitor revumenib produced complete remissions (CR) or complete remissions with a partial hematologic recovery (CRh) in 30% of patients with ...
2022 ELN Genetic-Risk Stratification Does Not Predict Outcomes Better Than 2017 Stratification for Adults With AML
Although the 2022 European LeukemiaNet (ELN) genetic-risk stratification accurately reflects outcomes with respect to complete remission (CR) and relapse rates, disease-free survival ...
Donor Age Matters More Than Donor Type in HCT for ALL
For a patient with acute lymphoblastic leukemia (ALL) who is undergoing hematopoietic cell transplant (HCT), using a haploidentical donor who is younger than 35 is likely to result in better survival outcomes ...
Telehealth Advanced Care Planning Conversations Benefit Older Patients With AML, MDS
Advanced care planning (ACP) can be successfully delivered to older patients with hematologic malignancies using telehealth, according to the results of a study ...
IDH Inhibitor Olutasidenib Active With or Without Azacitidine in IDH1-Mutated AML
Treatment with olutasidenib led to durable remission and mutation clearance in patients with relapsed or refractory (R/R) IDH1-mutated acute myeloid leukemia (AML) with or without azacitidine ...
Addition of Daratumumab to Standard Therapy Does Not Increase Cardiac Events in AL Amyloidosis
Across all cardiac stages (I-IIA), patients with newly diagnosed light chain (AL) amyloidosis treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone (D-VCd) had better outcomes than those treated with VCd ...
Small Percentage of aPL-Positive Patients Without Autoimmune Diseases Received Immunosuppression
About 15% of patients with persistently positive antiphospholipid antibodies (aPLs) without other systemic autoimmune disease were found to have received immunosuppression other than corticosteroids or hydroxychloroquine for certain aPL manifestations ...
Dasatinib/Prednisone Induction Followed by Blinatumomab/Dasatinib May Be an Alternative to Transplant in Ph+ ALL
Use of the anti-CD19 bispecific T-cell engaging antibody blinatumomab given in conjunction with the tyrosine kinase inhibitor (TKI) dasatinib may provide an alternative to allogenic transplant for older adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia ...
